Managing Patient Pathways and Improving Outcomes in NAFLD and NASH

Tuesday, August 6, 1:45 – 2:45 p.m.
Exhibit Hall, Theater 1
Supported by Siemens Healthineers


Nonalcoholic fatty liver disease (NAFLD), in which fat deposits in the liver, affects over 1 billion people globally and is projected to become the leading cause of liver-related mortality within 20 years. Learn about current testing options that address this unmet clinical need.


Attendees will:

  • Understand the epidemiology of NAFLD and nonalcoholic steatohepatitis.
  • Review practice guidelines and challenges in disease management.
  • Learn about therapies and how noninvasive blood tests can help manage the NAFLD pathway.


Andrew Beard 
Siemens Clinical Laboratory
New York, NY


Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF
Chairman of Department of Medicine, Inova Fairfax Medical Campus
Professor of Medicine
Virginia Commonwealth University Inova Campus
Affiliate Professor of Biomedical Sciences
George Mason University
Fairfax, VA

Arun J. Sanyal, MD
Professor of Department of Internal Medicine
Division of Gastroenterology, Hepatology and Nutrition
Virginia Commonwealth University
Richmond, VA